Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Jun 2009 17:15

RNS Number : 4872T
Skyepharma PLC
05 June 2009
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

SkyePharma Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Delta adjustment

X

3. Full name of person(s) subject to the notification obligation: iii

D. E. Shaw & Co., L.P. 

D. E. Shaw & Co. (U.K.), Ltd. 

4. Full name of shareholder(s)  (if different from 3.):iv

N/A

5. Date of the transaction and date on which the threshold is crossed or reached: v

June 3, 2009

6. Date on which issuer notified:

June 5, 2009

7. Threshold(s) that is/are crossed or reached: vi, vii

35%

  

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/  Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Contract for Differences ("CfD") relating to convertible bond due 2024

March 4, 2010

3,223,697

Nominal

Delta

13.85%

CfD relating to convertible bond due 2025

November 30, 2009

2,506,326

Nominal

Delta

10.77%

CfD relating to convertible bond due 2025

June 3, 2010

2,506,326

Nominal

Delta

10.77%

Total (A+B+C)

Number of voting rights

Percentage of voting rights

8,236,349

35.40%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Each of D. E. Shaw & Co., L.P. ("DESCO LP") and D. E. Shaw & Co. (U.K.), Ltd. ("DESCO UK") is notifying solely in its capacity as a discretionary investment manager. As general partner of DESCO LP, D. E. Shaw & Co., Inc. ("DESCO Inc.") is a parent undertaking of DESCO LP and DESCO UK. By virtue of David E. Shaw's position as president and sole shareholder of DESCO, Inc., which is the general partner of DESCO LP, David E. Shaw is a parent undertaking of DESCO LP and DESCO UK.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Stephen Back (Compliance Department)

15. Contact telephone number:

+1 212-478-0000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLQELFBKQBFBBL
Date   Source Headline
8th May 20067:02 amRNSConference Call Details
8th May 20067:01 amRNSFlutiform Deal
3rd May 20069:57 amRNSShare Purchase Plan
2nd May 200611:23 amRNSNotification of Shares
28th Apr 20067:02 amRNSEuropean Approval of Depodur
26th Apr 20062:32 pmRNSNotification of Interests
24th Apr 20064:23 pmRNSDirectors Share Awards
24th Apr 20062:29 pmRNSNotification of Interests
24th Apr 20061:38 pmRNSHolding(s) in Company
21st Apr 200611:16 amRNSPropofol Update
19th Apr 20067:02 amRNSPreliminary Results
5th Apr 20062:00 pmRNSBoard Appointment
3rd Apr 20065:43 pmRNSShare Purchase Plan
27th Mar 20069:06 amRNSNotice of Results
17th Mar 200610:15 amRNSNotification of Shares
15th Mar 20062:57 pmRNSNotification of Shares
14th Mar 20067:03 amRNSAgreement over Non-Executives
9th Mar 20063:46 pmRNSResult of EGM
6th Mar 20061:10 pmRNSHolding(s) in Company
3rd Mar 20065:06 pmRNSFinancial Position
3rd Mar 20064:12 pmRNSNotification of Shares
3rd Mar 200610:59 amRNSRule 8.3- Skyepharma PLC
2nd Mar 20064:58 pmRNSResponse to NAV
2nd Mar 20069:59 amRNSResponse to NAV
2nd Mar 20067:40 amRNSEGM Statement
1st Mar 20064:43 pmRNSShare Purchase Plan
27th Feb 20069:37 amRNSEGM Nominee Voting
23rd Feb 20062:14 pmRNSNotification of Shares
23rd Feb 200612:13 pmRNSNotification of Shares
16th Feb 20067:02 amRNSEGM Circular
15th Feb 20063:33 pmRNSDirector/PDMR Shareholding
14th Feb 20065:23 pmRNSNotification of Shares
13th Feb 20065:24 pmRNSNotification of Shares
13th Feb 200610:36 amRNSNotification of Shares
13th Feb 20067:01 amRNSFormer Chairman Retires
9th Feb 20062:34 pmRNSNotification of Shares
9th Feb 200612:35 pmRNSNotification of Shares
9th Feb 20067:01 amRNSFurther Re Employment Terms
8th Feb 20063:33 pmRNSNotification of Shares
7th Feb 20064:29 pmRNSNotification of Shares
7th Feb 20063:30 pmRNSResponse to NAV Syndicate
6th Feb 20063:26 pmRNSNotification of Shares
6th Feb 20063:23 pmRNSNotification of Shares
6th Feb 20067:01 amRNSBoard Appointment
3rd Feb 20063:22 pmRNSNotification of Shares
3rd Feb 200611:19 amRNSDirector Shareholding
3rd Feb 200611:12 amRNSDirector/PDMR Shareholding
3rd Feb 200610:37 amRNSDirector/PDMR Shareholding
2nd Feb 20063:20 pmRNSRule 8.3- (Skyepharma Group)
2nd Feb 200612:08 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.